We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 417.6 -0.3674% AAPL 233.8413 1.0987% NVDA 131.796 -4.5441% GOOGL 165.105 0.0879% GOOG 166.53 0.1082% AMZN 186.945 -0.3173% META 585.25 -0.8756% AVGO 176.46 -3.2088% TSLA 220.1722 0.4619% TSM 187.28 -2.5649% LLY 912.1201 -1.8709% V 279.38 -0.4632% JPM 223.51 0.9166% UNH 558.27 -7.7849% NVO 117.56 -1.8534% WMT 81.405 1.3887% LVMUY 129.75 -6.7888% XOM 120.9 -2.5629% LVMHF 649.99 -6.7827% MA 507.335 0.1332%

Effector Therapeutics Inc

Healthcare US EFTR

0.03134USD
-0.1487(82.59%)

Last update at 2024-10-15T18:54:00Z

52 Week Range

1.6037.00
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap8.23M
  • Volume70365
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-33.73300M
  • Revenue TTM0.68M
  • Revenue Per Share TTM0.35
  • Gross Profit TTM -19.76000M
  • Diluted EPS TTM-12.43

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -22.66500M 15.80M 14.56M -
Minority interest - - - -
Net income -12.92700M 15.80M 14.21M -
Selling general administrative 12.64M 13.37M 4.35M -
Selling and marketing expenses - - - -
Gross profit - 1.43M 42.00M -
Reconciled depreciation 0.05M 0.02M 0.16M -
Ebit -32.45600M -31.92100M 15.82M -28.60500M
Ebitda -32.40300M -31.89700M 16.05M -
Depreciation and amortization 0.05M 0.02M 0.24M -
Non operating income net other - 49.46M - -
Operating income -32.40300M -31.89700M 15.82M -
Other operating expenses 32.40M 31.90M 26.18M -
Interest expense 2.25M 1.76M 1.33M 0.00000M
Tax provision - 0.00000M 0.35M -
Interest income 0.44M 0.00600M 0.07M -
Net interest income -1.81200M -1.75800M -1.26600M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -9.73800M -0.02400M 0.35M -
Total revenue 0.00000M 1.43M 42.00M -
Total operating expenses 32.40M 31.90M 26.18M -
Cost of revenue - - - -
Total other income expense net 9.74M 47.70M -1.25700M -
Discontinued operations - - - -
Net income from continuing ops -22.66500M 15.80M 14.21M -
Net income applicable to common shares -22.66500M 15.80M 0.17M -14.21000M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 20.54M 29.08M 54.06M 16.70M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.42M 1.70M 3.19M 1.36M -
Total liab 26.34M 25.18M 36.77M 148.95M -
Total stockholder equity -5.79500M 3.90M 17.28M -132.24500M -
Deferred long term liab - - - - -
Other current liab 4.02M 3.37M 3.42M 0.43M 0.44M
Common stock - 0.00400M 0.00400M 0.00045M 0.00100M
Capital stock 0.00000M 0.00400M 0.00400M 0.00000M -
Retained earnings -179.37700M -143.56600M -120.90100M -136.69900M -150.91000M
Other liab - 0.05M 12.81M - -
Good will - - - - -
Other assets 0.00000M 0.71M 0.90M 0.18M -
Cash 14.88M 8.71M 49.70M 15.22M -
Cash and equivalents - - - - -
Total current liabilities 25.80M 25.07M 3.98M 8.78M 18.93M
Current deferred revenue - - - 1.98M -
Net debt 4.57M 11.57M -29.67200M -2.25500M -
Short term debt 19.45M 20.22M 0.04M 6.01M -
Short long term debt 20.48M 20.16M - 5.91M -
Short long term debt total 19.45M 20.28M 20.03M 12.96M -
Other stockholder equity 173.58M 147.48M 138.18M 4.45M -
Property plant equipment - 0.35M 0.09M 0.13M 0.82M
Total current assets 19.84M 28.01M 52.90M 16.58M 4.27M
Long term investments - - - - -
Net tangible assets - 3.90M 17.28M -132.24500M -147.06300M
Short term investments 3.50M 17.60M - - -
Net receivables 0.05M 0.03M 0.10M - -
Long term debt - - 19.86M 6.95M -
Inventory - - - - -
Accounts payable 2.33M 1.49M 0.52M 0.35M 0.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M -0.01800M -54.05600M - -
Additional paid in capital - - - - -
Common stock total equity - - 0.00400M 0.00045M -
Preferred stock total equity - - - - -
Retained earnings total equity - - -120.90100M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.51M 0.71M 0.90M - -
Deferred long term asset charges - - - - -
Non current assets total 0.71M 1.06M 1.16M 0.13M -
Capital lease obligations 0.06M 0.12M 0.17M 0.11M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -17.86000M 0.56M -0.15400M -17.66800M
Change to liabilities 0.96M 1.95M -0.25100M -0.72700M
Total cashflows from investing activities -17.86000M 0.56M -0.15400M 0.08M
Net borrowings - 19.84M -2.00000M -2.00000M
Total cash from financing activities 2.77M 58.81M -1.89200M 20.24M
Change to operating activities 1.72M -0.39300M -0.57300M 1.80M
Net income -22.66500M 15.80M 14.21M -14.21000M
Change in cash -40.99400M 34.49M 11.79M -7.27100M
Begin period cash flow 49.70M 15.22M 3.43M -
End period cash flow 8.71M 49.70M 15.22M 3.43M
Total cash from operating activities -25.89900M -24.88800M 13.84M -27.59800M
Issuance of capital stock 2.80M - - -
Depreciation 0.05M 0.02M 0.16M 0.31M
Other cashflows from investing activities - 0.56M - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - 0.06M - -
Other cashflows from financing activities -0.03400M 72.75M 0.11M -0.09300M
Change to netincome -5.96400M 8.44M 14.33M -14.76600M
Capital expenditures 0.19M 0.04M 0.15M 0.00400M
Change receivables - - - -
Cash flows other operating - -51.09400M - -
Exchange rate changes - - - -
Cash and cash equivalents changes - 34.49M - -
Change in working capital 2.68M -0.23800M -0.82400M -
Stock based compensation 5.33M 8.66M 0.50M -
Other non cash items -11.29800M -48.59300M 0.12M -
Free cash flow -26.09100M -24.93000M 13.68M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EFTR
Effector Therapeutics Inc		 -0.1487 82.59% 0.03 - - 69.65 13.38 -0.3003
NVO
Novo Nordisk A/S		 -2.22 1.85% 117.56 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.45 0.38% 119.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.745 0.36% 483.07 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.10 0.0099% 1014.35 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Effector Therapeutics Inc

142 North Cedros Avenue, Solana Beach, CA, United States, 92075

Key Executives

Name Title Year Born
Dr. Stephen T. Worland Ph.D. CEO, Pres & Director 1958
Mr. Michael Byrnes M.B.A. Chief Financial Officer 1977
Dr. Siegfried Reich Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board 1960
Dr. Davide Ruggero Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Kevan M. Shokat Ph.D. Co-Founder and Member of Clinical & Scientific Advisory Board NA
Dr. Douglas Warner M.D. Chief Medical Officer NA
Dr. Mayank J. Gandhi M.D. Chief Bus. Officer 1978
Dr. Stephen T. Worland Ph.D. CEO, President & Director 1958
Dr. Douglas Warner M.D. Chief Medical Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.